Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia.

Article / By

This real-world study evaluates the safety and efficacy of Palbociclib in HR-positive, HER2-negative metastatic breast cancer patients in Saudi Arabia, revealing a median progression-free survival of 22 months and overall survival of 26.46 months. Neutropenia was the most common adverse event, affecting 41.2% of patients, highlighting the need for careful monitoring and management of side effects.

Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia. Read More »

Association of initial abemaciclib dosing with duration of medication use in patients with stage II/III breast cancer on endocrine therapy.

Article / By

The research investigates the impact of initial dosing of abemaciclib on the duration of medication use in patients with stage II/III breast cancer undergoing endocrine therapy. It finds that starting at a lower dose (50mg BID) is associated with a longer average duration of use compared to higher doses, although overall treatment duration and discontinuation rates remain similar. The study suggests the need for further prospective research on alternative dosing regimens to enhance treatment adherence and outcomes.

Association of initial abemaciclib dosing with duration of medication use in patients with stage II/III breast cancer on endocrine therapy. Read More »

A single center experience of PIK3CA and AKT inhibitors in patients with hormone receptor positive metastatic breast cancer.

Article / By

This study analyzes the efficacy and safety of PI3K/AKT inhibitors (alpelisib, capivasertib, and inavolisib) in patients with hormone receptor-positive metastatic breast cancer. The findings indicate that the median progression-free survival for alpelisib and capivasertib were 5.8 months and 7.6 months, respectively, with lower rates of dose interruptions and diarrhea observed compared to clinical trial data.

A single center experience of PIK3CA and AKT inhibitors in patients with hormone receptor positive metastatic breast cancer. Read More »

CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications.

Article / By

This study evaluates the effects of combining cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with radiotherapy (RT) in patients with hormone receptor-positive, HER2-negative breast cancer, finding that while this combination improves disease-free survival and overall survival, it also increases hematologic toxicities, particularly leukopenia. The results indicate that despite the heightened risk of side effects, the concurrent or sequential use of RT with CDK4/6i is beneficial and manageable in clinical practice.

CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications. Read More »

Palbociclib-Induced Subacute Cutaneous Lupus

Article / By

The research discusses a case of a 54-year-old woman who developed subacute cutaneous lupus after starting treatment with palbociclib and letrozole for metastatic breast cancer. The skin biopsy revealed features consistent with this condition, and discontinuation of palbociclib led to spontaneous improvement of the rash. The study highlights the need to recognize skin toxicities associated with CDK 4/6 inhibitors to ensure effective treatment and continuation of oncology therapies.

Palbociclib-Induced Subacute Cutaneous Lupus Read More »

Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences

Article / By

This study investigates the incidence and management of diarrhoea in patients with hormone-receptor positive, HER2-negative metastatic breast cancer receiving abemaciclib and endocrine therapy. It finds that a significant number of participants experienced diarrhoea, which negatively impacted their quality of life and treatment adherence, highlighting the need for better symptom monitoring and supportive interventions.

Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences Read More »

Perceptions, educational expectations and knowledge gaps of patients with non-metastatic breast cancer regarding radiotherapy: Integrative review

Article / By

This integrative review examines the perceptions, educational expectations, and knowledge gaps of patients with non-metastatic breast cancer regarding radiotherapy. The findings reveal that patients’ views on radiotherapy are shaped by their understanding of the treatment and its effects, and they seek education on various aspects of the treatment process. The study emphasizes the need for tailored, culturally sensitive education and individualized communication strategies to address these gaps and improve patient outcomes.

Perceptions, educational expectations and knowledge gaps of patients with non-metastatic breast cancer regarding radiotherapy: Integrative review Read More »

Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom?

Article / By

This research discusses the adjuvant treatment options for early hormone receptor-positive, HER2-negative breast cancer, highlighting the roles of targeted therapies such as abemaciclib, ribociclib, and olaparib. These treatments have shown significant improvements in invasive disease-free survival for patients at high risk of recurrence, necessitating careful consideration of their benefits and potential side effects by healthcare providers.

Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom? Read More »

Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer

Article / By

This study found that 43% of patients with hormone receptor-positive, HER2-negative breast cancer were non-adherent to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), with older age and Hispanic ethnicity being associated with non-adherence. Non-adherence negatively impacted overall and progression-free survival, indicating a need for interventions to enhance adherence in this patient population.

Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer Read More »

Understanding the prospective of gene therapy for the treatment of breast cancer

Article / By

The research discusses the potential of gene therapy as a transformative approach for treating breast cancer, which is the most common cancer among women. It highlights recent advancements in targeted gene treatments, including CRISPR and CAR-T therapy, that enhance specificity and efficiency in cancer treatment.

Understanding the prospective of gene therapy for the treatment of breast cancer Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm